SINCALIDE FOR INJECTION POWDER FOR SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

SINCALIDE

Διαθέσιμο από:

AVIR PHARMA INC.

Φαρμακολογική κατηγορία (ATC):

V04CC03

INN (Διεθνής Όνομα):

SINCALIDE

Δοσολογία:

5MCG

Φαρμακοτεχνική μορφή:

POWDER FOR SOLUTION

Σύνθεση:

SINCALIDE 5MCG

Οδός χορήγησης:

INTRAVENOUS

Μονάδες σε πακέτο:

15G/50G

Τρόπος διάθεσης:

Ethical

Θεραπευτική περιοχή:

GALLBLADDER FUNCTION

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0113162001; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2019-11-22

Αρχείο Π.Χ.Π.

_SINCALIDE FOR INJECTION (sincalide) _
_Page 1 of 16_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
SINCALIDE FOR INJECTION
Sincalide for Injection
Powder for Solution, 5 mcg / vial, Intravenous
House Std.
Diagnostic Cholecystokinetic
AVIR PHARMA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.avirpharma.com
Date of Initial Authorization:
November 22, 2019
Date of Revision:
October 20, 2022
Submission Control Number: 264855
_SINCALIDE FOR INJECTION (sincalide) _
_Page 2 of 16_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.3
Reconstitution
...................................................................................................
5
5
OVERDOSAGE
.............................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA